Fruquintinib Hepatic Impairment Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

October 25, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

Fruquintinib

Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions

Trial Locations (2)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology of Miami, Miami